Professor Emeritus, UCL
Founder, Senior Research Adviser
Xenetic Biosciences Inc.
Professor Gregory Gregoriadis is the Founder (1997) of Xenetic Biosciences Inc and creator of the company's polysialic acid and liposome technologies. He was a Board member, and CSO (1997-2015), Head of the Centre for Drug Delivery Research(1990-2001) at University College London, and Head of the Liposomes Group at the Medical Research Council (1972-1990). In 1971 he introduced (with B. Ryman) liposomes for drug and vaccine delivery and, in 1991, introduced polysialic acid to improve the pharmacokinetics and pharmacodynamics of protein and peptide drugs. He has published nearly 400 research papers, reviews, articles and book chapters, and 27 volumes on drug and vaccine delivery. Gregory's work has been honoured with the Controlled Release Society Founders Award (1994), the A.D. Bangham FRS Life Achievement Award (1995), a Fellowship in the American Association of Pharmaceutical Scientists (1998), a Fellowship in the Controlled Release Society(2013), a DSc from the University of London (2001), the Journal of Drug Targeting Life Achievement Award (2008), a Fellowship in the Academy of Pharmaceutical Scientists (2008), and the Founders Award of Liposome Research Days (2010), all for exceptional contributions to the field of drug and vaccine delivery. Gregory's seminal contributions are also reflected in his founding (1978) of the Gordon Research Conference series 'Drug Carriers in Medicine and Biology', his directorships of two NATO Advanced Studies Institute series: 'Drug Targeting' and 'Vaccines' (1981-1999), his founding of the 'Liposome Advances' conference series (1991-2015), and his position of Professor Emeritus at University College London.
Drug delivery, Liposomal delivery, vaccine delivery, Advances in drug Delivery